The Gates Foundation’s new AI initiative: attempting to leapfrog global health inequalities?
By Jonathan Shaffer, Arsenii Alenichev, and Marlyn C. Faure,
BMJ Global Health
| 11. 03. 2023
The Bill & Melinda Gates Foundation has long been criticised for championing the trend of socially reductive, ‘magic bullet’ technical ‘solutions’ to the complex, historically shaped, politically conflicted problems at root of global health inequities.1–5 Their August 9th announcement of the launch of a new US$5 million, 48 project funding push6 to launch new ‘artificial intelligence (AI) large language models (LLM) in low-income and middle-income countries to improve the livelihood and well-being of communities globally’ is set to continue this hegemonic global health trend. And, as much as ‘magic bullets’ can solve issues, they, as bullets, are also capable of wounding and causing harm.
There are at least three reasons to believe that the unfettered imposition of these tools into already fragile and fragmented healthcare delivery systems risks doing far more harm than good.
We are not Luddites. New tools of technology, biomedicine, scientific knowledge and population care have often made life better and safer for those with access and control over their use.7 LLMs and AI, however, will not be so equity-advancing despite the Gates Foundation’s overheated...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...